Physician profile
Robert Franklin Moreland
NPI 1790712842
$17,978.21
in general payments reported to CMS, 2019-2025
28 companies · $3,716 in 2025
The $3,716 reported for 2025 was more than what 87% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,371 · 2020: $256 · 2021: $1,676 · 2022: $2,934 · 2023: $4,198 · 2024: $3,827 · 2025: $3,716.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Education: $361.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,380.67 |
| Education | $360.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $4,191.47 | 2019-2025 | |
| Janssen Biotech, INC. | $2,523.01 | 2019-2025 | Tremfya, Simponi Aria, Simponi |
| Genzyme Corporation | $1,636.19 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $1,451.57 | 2019-2025 | |
| Ucb, INC. | $1,152.34 | 2019-2025 | Bimzelx, Cimzia |
| Sun Pharmaceutical Industries INC. | $1,152.01 | 2019-2025 | Ilumya |
| Lilly USA, LLC | $1,069.73 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Regeneron Healthcare Solutions, INC. | $812.54 | 2019-2025 | Libtayo, Dupixent |
| E.R. Squibb & Sons, L.L.C. | $792.39 | 2022-2025 | Sotyktu |
| Amgen INC. | $571.57 | 2019-2025 | Otezla, Otezla |
| Leo Pharma INC. | $515.97 | 2021-2025 | Adbry, Anzupgo |
| Pfizer INC. | $414.08 | 2019-2025 | |
| Arcutis Biotherapeutics, INC. | $405.40 | 2023-2025 | Zoryve |
| Incyte Corporation | $295.48 | 2022-2025 | Opzelura |
| Galderma Laboratories, L.P. | $182.71 | 2024-2025 | Nemluvio |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Blueprint Medicines Corporation | $114.00 | 2023 | Ayvakit |
| Merck Sharp & Dohme LLC | $106.34 | 2019 | |
| Eli Lilly and Company | $99.00 | 2025 | |
| Dusa Pharmaceuticals, INC. | $86.97 | 2019 | |
| Strata Skin Sciences, INC. | $82.64 | 2022-2024 | Xtrac |
| Dermavant Sciences, INC. | $65.57 | 2023-2024 | Vtama |
| Genentech USA, INC. | $62.38 | 2019-2021 | |
| Smith+Nephew, INC. | $54.40 | 2019 | |
| Celgene Corporation | $50.23 | 2019 | |
| Helsinn Therapeutics (U.S.), INC. | $27.64 | 2019 | |
| Kyowa Kirin, INC. | $25.24 | 2024 | Poteligeo |
| Sanofi-Aventis U.S. LLC | $23.95 | 2021 | |
| Organon LLC | $13.39 | 2025 | Vtama |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Moreland listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.